The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient
| Autor: | Jack Wang, Peter A Bluestone, Richard N. Pierson, Jerrilynn D. Burrowes |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
medicine.medical_specialty media_common.quotation_subject medicine.medical_treatment Body water Serum albumin Medicine (miscellaneous) Appetite Stimulants Nutritional Status Renal Dialysis Internal medicine Extracellular fluid medicine Humans media_common chemistry.chemical_classification Nutrition and Dietetics biology Dose-Response Relationship Drug business.industry Megestrol Acetate Appetite Middle Aged Endocrinology Poor Appetite chemistry Nephrology Transferrin Megestrol acetate biology.protein Body Composition Hemodialysis business medicine.drug |
| Zdroj: | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 9(2) |
| ISSN: | 1051-2276 |
| Popis: | Objective: To determine the safety and efficacy of moderate doses of megestrol acetate (≥320 mg/day) in a patient on hemodialysis. Design: Case study. Setting: Chronic hemodialysis facility and body composition unit in New York City. Main outcome measures: Body weight, body composition, dietary energy and protein intake, appetite assessment, serum albumin, prealbumin, serum transferrin, and quality of life. Results: The patient received megestrol acetate for 24 weeks and gained little body weight. However, his fat mass increased by 7.5 kg (163%), and fat-free mass decreased by 6.8 kg (10.6%) from baseline measurements. The proportional content of total body water, extracellular water, intracellular water, body cell mass in fat-free mass, and average cell K + concentration were maintained within normal ranges. Serum albumin was maintained, serum transferrin increased, prealbumin decreased, dietary energy and protein intakes increased, and reported appetite improved. Conclusions: Moderate doses of megestrol acetate may be an effective therapeutic agent in reversing poor appetite, increasing dietary energy and protein intakes, and improving nutritional status in some patients receiving maintenance hemodialysis. However, these changes were at the expense of altering body composition components. Further research that includes measures of body composition, nutritional status, appetite assessment, and quality of life are needed to determine the safety and effectiveness of moderate or high doses of megestrol acetate in a large number of hemodialysis patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|